Pelthos Therapeutics Inc.

PTHS · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances)
55
SEC Filings

Business Summary

PART I Overview Pelthos Therapeutics Inc. (the Company) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI , and XEGLYZE . The July 1, 2025 merger transaction between Channel Therapeutics Corporation ...

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPTHSdiscussed_in_filing Cybersecurity
topic_mentionPTHSdiscussed_in_filing Trusted Computing
topic_mentionPTHSdiscussed_in_filing Blockchain & Crypto
topic_mentionPTHSdiscussed_in_filing Supply Chain
topic_mentionPTHSdiscussed_in_filing Regulation
topic_mentionPTHSdiscussed_in_filing Healthcare & Bio
topic_mentionPTHSdiscussed_in_filing Platform & Ecosystem
topic_mentionPTHSdiscussed_in_filing Sovereign & Government
topic_mentionPTHSdiscussed_in_filing Cybersecurity
topic_mentionPTHSdiscussed_in_filing Trusted Computing
topic_mentionPTHSdiscussed_in_filing Blockchain & Crypto
topic_mentionPTHSdiscussed_in_filing Supply Chain
topic_mentionPTHSdiscussed_in_filing Regulation
topic_mentionPTHSdiscussed_in_filing Healthcare & Bio
topic_mentionPTHSdiscussed_in_filing Platform & Ecosystem
topic_mentionPTHSdiscussed_in_filing Sovereign & Government
topic_mentionPTHSdiscussed_in_filing Cybersecurity
topic_mentionPTHSdiscussed_in_filing Trusted Computing
topic_mentionPTHSdiscussed_in_filing Blockchain & Crypto
topic_mentionPTHSdiscussed_in_filing Supply Chain

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001919246-26-000013EDGAR113K words
2025-03-272024-12-310001753926-25-000503EDGAR—
2024-04-162023-12-310001753926-24-000740EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001753926-25-001764EDGAR51K words
2025-08-132025-06-300001753926-25-001326EDGAR—
2025-05-132025-03-310001753926-25-000790EDGAR—
2024-11-132024-09-300001753926-24-001883EDGAR—
2024-08-132024-06-300001753926-24-001423EDGAR—
2024-05-152024-03-310001753926-24-000976EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001919246-26-000014EDGAR4K words
2026-01-130001753926-26-000097EDGAR—
2026-01-120001753926-26-000094EDGAR—
2026-01-020001753926-26-000010EDGAR—
2025-12-230001753926-25-001964EDGAR—
2025-12-170001753926-25-001906EDGAR—
2025-11-130001753926-25-001766EDGAR—
2025-11-070001753926-25-001715EDGAR—
2025-10-140001753926-25-001606EDGAR—
2025-09-030001753926-25-001425EDGAR—

55 total filings indexed. 36 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001919246
TickerPTHS
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedNV

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: cfbf09e2f843a3460b81386c76efa61913acb3776ecb6bfdc242be5fcca7a385
parent: 08832ab380e9751c95261ea0346b046ad9b8716ffb5b74d5e081a4f81e2562c5
content hash: 5c48e8fa38cb3d427265d593076a67146f2e889e5fdb4ec146362ae433bf05be
signed: 2026-04-13T04:47:02.723Z
sources: 9 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf